Shenfu injection combined with furosemide in the treatment of chronic heart failure in patients with coronary heart disease

Abstract

Background: Coronary heart disease (CHD) is an important cause of chronic heart failure, and chronic heart failure is also a serious complication in the end stage of coronary heart disease. At present, there is no specific treatment plan. Shenfu injection has advantages in the treatment of heart failure in patients with coronary heart disease, but there is a lack of standard clinical study to verify this. Therefore, the purpose of this randomized controlled trial is to evaluate the efficacy and safety of Shenfu injection combined with furosemide in the treatment of chronic heart failure in patients with coronary heart disease. Methods: This is a prospective randomized controlled trial to study the efficacy and safety of Shenfu injection combined with furosemide in the treatment of coronary heart disease and chronic heart failure. This study will be approved by the clinical research ethics committee of our hospital. The patients will be randomly divided into two groups according to 1:1:(a) Shenfu injection combined with furosemide group and (b) simple furosemide group. Standard treatment for 7 days followed up for 30 days at the same time, pay attention to its efficacy and safety indicators. The total effective rate of cardiac function improvement, left ventricular ejection fraction (LVEF), N-terminal pro-brain natriuretic peptide (NT-pro BNP), 6-minute walk test (6-MWTD), and adverse reactions will be observed. Data will be analyzed using the statistical software package SPSS version 25.0 (Chicago, IL). Discussion: This study will evaluate the efficacy and safety of Shenfu injection combined with furosemide in the treatment of coronary heart disease with chronic heart failure. The results of this experiment will provide a clinical basis for Shenfu injection combined with furosemide in the treatment of coronary heart disease and chronic heart failure. OSF Registration number: doi: 10.17605/OSF.IO/27FPM

Characteristic analysis of clinical coronary heart disease and coronary artery disease concerning young and middle-aged male patients

“…In more severe cases, coronary artery stenosis or occlusion occurs, and the myocardial blood supply continuously decreases and can even terminate. This can result in severe myocardial ischemia or myocardial necrosis that leads to myocardial infarction and related complications, which have a serious impact on the life and health of patients[ 8 , 9 ]. As CHD tends to occur in younger people, the after-illness impact on reduced quality of life, labor loss, and prognosis in young patients is far greater than those on middle-aged patients.…”

Protective Effect of Ginsenoside Rg5 on Hypoxia/Reoxygenation- Induced H9c2 Cardiomyocytes by Correcting Free Fatty Acids β- oxidation

“…Therefore, we turned our attention to Chinese herbal medicines and their prescriptions. In China, clinical trials [24,[50][51][52][53][54] have demonstrated that SFI has a good therapeutic effect and high safety. The main active components of SFI are ginsenosides and alkaloids.…”

Shenfu Administration Improves Cardiac Fibrosis in Rats With Myocardial Ischemia-Reperfusion Through Adenosine A2a Receptor Activation

“…SFI, a traditional Chinese medicine, has typically been used in China for cardiac disorders such as heart failure 21,22 and AMI. 13,23 Multiple mechanisms of action accounting for improved myocardial function with SFI have been reported, including anti-oxidation, 24,25 anti-inflammation, 24,26 and anti-fibrosis.…”

“…For myocardial fibrosis induced by MI/R, injection of SFI prior to reperfusion could be greatly reduced by suppressing the expression of collagen I, collagen III, fibronectin, and MMP-9 proteins. SFI, a traditional Chinese medicine, has typically been used in China for cardiac disorders such as heart failure 21,22 and AMI. 13,23 Multiple mechanisms of action accounting for improved myocardial function with SFI have been reported, including anti-oxidation, 24,25 anti-inflammation, 24,26 and anti-fibrosis.…”